Amgen and Eli Lilly Adopt Veeva CRM, Supporting Market Pivot
What happened
Amgen and Eli Lilly announced major commitments to adopt Veeva's CRM platform. These deals support Veeva's strategic pivot toward the life sciences CRM market. Jim Cramer also discussed Veeva's recovery from AI fears, noting the company's specialized software for the pharma and biotech industries.
From insidermonkey.com
Why it matters
The adoption by major drugmakers validates Veeva Systems' specialized software and its move onto the newer commercial platform. This market validation occurred as Veeva highlighted the incorporation of AI into its products.
Veeva Systems is strategically pivoting its operations, targeting the life sciences CRM market while transitioning from Salesforce's cloud infrastructure to its proprietary Vault platform.
From insidermonkey.com
Who's involved
- AmgenAmgen, which committed to adopting Veeva's CRM platform.
- Eli Lilly and CompanyEli Lilly and Company, which committed to deploying Vault CRM globally.
- Veeva SystemsVeeva Systems, the provider of the specialized CRM platform.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Veeva SystemsSpeculative
Veeva Systems could see significant revenue growth from major customer adoption.
- AmgenSpeculative
Amgen might incur operational cost changes due to platform migration to Veeva's system.
- SalesforceSpeculative
Salesforce may face increased pressure on its CRM market share due to Veeva's customer wins.
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company